PATENT CLAIM ANALYSIS

Application Number: 15885273
Application Type: Utility
Filing Date: 2018-01
Publication Date: 2018-08
Patent Classification: ["514", "443000"]

Abstract:
Disclosed herein are methods for treatment of estrogen-related medical disorders. The methods of treatment may comprise administering to a subject in need of such treatment a composition comprising a therapeutically effective amount of at least one compound of formula (I) or a pharmaceutically acceptable salt thereof.

Claim (Index 9):
A method of identifying a cancer in a subject, the method comprising:\n (a) obtaining a test sample from the subject having cancer; and (b) determining an amount of protein kinase C alpha (PKC\u03b1) in the test sample; wherein if the amount of PKC\u03b1 in the test sample is greater than an amount of PKC\u03b1 in a test sample from a subject not having cancer, then the cancer is sensitive to at least one compound of formula (I) or a pharmaceutically acceptable salt thereof, wherein R 1  is selected from the group consisting of hydrogen, alkyl, \u2014SO 3 R x1 , \u2014PO 3 R y1 R z1 , and \u2014C(\u2550O)R a ; R 2  is selected from the group consisting of halo and \u2014OR 3 ; R 3  is selected from the group consisting of hydrogen, alkyl, \u2014SO 3 R x1 , \u2014PO 3 R y1 R z1 , and \u2014C(\u2550O)R a ; A 1  is H, alkyl, \u2014R b1 , \u2014OR b2 , or \u2014C(\u2550O)R b3 ; R b1 , R b2 , and R b3  are each independently selected from the group consisting of is alkyl, cycloalkyl, and phenyl substituted with 1, 2, or 3 substituents independently selected from halo and \u2014OR 4 ; R 4  is selected from the group consisting of hydrogen, alkyl, \u2014SO 3 R x1 , \u2014PO 3 R y1 R z1 , and \u2014C(\u2550O)R a ; R a , at each occurrence, is independently selected from the group consisting of \u2014OH and alkyl; and R x1 , R y1  and R z1  are, at each occurrence, independently selected from the group consisting of hydrogen and a pharmaceutically acceptable cation; provided that the compound of formula (I) contains at least one group selected from \u2014OR 3  and \u2014OR 4 ; provided that 2-(4-fluorophenyl)-3-(4-hydroxyphenoxy)benzo[b]thiophen-6-ol is excluded from the compound of formula (I).

Metadata:
- Claim Count in Document: 39.0
- Percentile: 86.0
- Lexical Diversity: 1.28205
- Patent Class: 514.0
- Transitional Phrase Type: open
- Component Type: 1
- Foreign Priority: False
- Related Applications: ['14438326', '15264407', '15382338', '15764988', '13181978']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7849769152500203
- 35 USC 102 Novelty (BERT): 0.6145971460673284
- Combined Prediction Score: 0.7679389383317512
- Mean Citation Score: 452.763606
- Max Citation Score: 693.1075
- Similarity Product: 474.4039767581224

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test